alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT
32.1





CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER


PURSUANT
TO 18 U.S.C. § 1350





(SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002)





I, Song
Jinan, Chief Executive Officer (principal executive officer) of China-Biotics,
Inc. (the “Registrant”), certify pursuant to 18 U.S.C. § 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based upon a
review of the Quarterly Report on Form 10-Q for the period ended June 30, 2010
of the Registrant (the “Report”):





(1) The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended; and





(2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the
Registrant.





A signed
original of this written statement required by Section 906 has been provided to
the Registrant and will be retained by the Registrant and furnished to the
Securities and Exchange Commission or its staff upon request.




/s/ Song JinanSong
      JinanChief
      Executive OfficerAugust
      9, 2010
----

            COUNCIL REGULATION (EC) No 700/2006

of 25 April 2006         

repealing Regulation (EC) No 3690/93 establishing a Community system laying down rules for the minimum information to be contained in fishing licences

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty establishing the European Community, and in particular Article 37 thereof,

Having regard to the proposal from the Commission,

Having regard to the opinion of the European Parliament (1),

Whereas:

HAS ADOPTED THIS REGULATION:

Article 1

1.   Regulation (EC) No 3690/93 is hereby repealed.

2.   References to the repealed Regulation shall be construed as references to Regulation (EC) No 1281/2005 and shall be read in accordance with the correlation table set out in the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the seventh day following its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Luxembourg, 25 April 2006.

For the Council

The President

J. PRÖLL            

----

(1)  Not yet published in the Official Journal.

(2)OJ L 341, 31.12.1993, p. 93.

(3)OJ L 389, 31.12.1992, p. 1. Regulation as last amended by Regulation (EC) No 1181/93 (OJ L 164, 9.6.1998, p. 1).

(4)OJ L 358, 31.12.2002, p. 59.

(5)OJ L 203, 4.8.2005, p. 3.

----

ANNEX

Correlation table

----
# Official Journal C 33E/2009

| | ISSN 1725-2423 |
| --- | --- |
| Official Journal
  of the European Union | C 33E |
| | |
| English edition | Information and Notices | Volume 5210 February 2009 |

ISSN 1725-2423

Official Journal

of the European Union

C 33E

English edition

Information and Notices

Volume 5210 February 2009

---

| Notice No | Contents | page |
| --- | --- | --- |
| | III   Preparatory Acts |
| | COUNCIL |
| 2009/C 033E/01 | Common Position (EC) No 1/2009 of 17 December 2008 adopted by the Council, acting in accordance with the procedure referred to in Article 251 of the Treaty establishing the European Community, with a view to the adoption of a Regulation of the European Parliament and of the Council amending Regulation (EC) No 883/2004 on the coordination of social security systems, and determining the content of its annexes (1) | 1 |
| 2009/C 033E/02 | Common Position (EC) No 2/2009 of 18 December 2008 adopted by the Council, acting in accordance with the procedure referred to in Article 251 of the Treaty establishing the European Community, with a view to the adoption of a Regulation of the European Parliament and of the Council laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, and repealing Regulation (EEC) No 2377/90 (2) | 30 |

Notice No

Contents

page

III   Preparatory Acts

COUNCIL

2009/C 033E/01

Common Position (EC) No 1/2009 of 17 December 2008 adopted by the Council, acting in accordance with the procedure referred to in Article 251 of the Treaty establishing the European Community, with a view to the adoption of a Regulation of the European Parliament and of the Council amending Regulation (EC) No 883/2004 on the coordination of social security systems, and determining the content of its annexes (1)

1

2009/C 033E/02

Common Position (EC) No 2/2009 of 18 December 2008 adopted by the Council, acting in accordance with the procedure referred to in Article 251 of the Treaty establishing the European Community, with a view to the adoption of a Regulation of the European Parliament and of the Council laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, and repealing Regulation (EEC) No 2377/90 (2)

30

---

| | |
| --- | --- |
| 2009/C 033E/03 | Note to the reader(see page 3 of the cover) | s3 |

2009/C 033E/03

Note to the reader(see page 3 of the cover)

Note to the reader

s3

---

| | |
| --- | --- |
| | (1)   Text with relevance for the EEA and for Switzerland |
| | (2)   Text with EEA relevance |

---

(1)   Text with relevance for the EEA and for Switzerland

1

(2)   Text with EEA relevance

2

| EN | |
| --- | --- |

EN
I 

110TH CONGRESS 

1ST SESSION H. R. 4911 

To amend the Controlled Substances Act to add human growth hormone 

to schedule III. 

IN THE HOUSE OF REPRESENTATIVES 

DECEMBER 19, 2007 

Mr. LYNCH introduced the following bill; which was referred to the Committee 

on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each 

case for consideration of such provisions as fall within the jurisdiction of 

the committee concerned 

A BILL 

To amend the Controlled Substances Act to add human 

growth hormone to schedule III. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Human Growth Hor5 mone Restriction Act of 2007’’. 

6 SEC. 2. HUMAN GROWTH HORMONE. 

7 (a) IN GENERAL.—Schedule III of section 202(c) of 

8 the Controlled Substances Act (21 U.S.C. 812(c)) is 

9 amended by adding at the end the following: 


bajohnson on PROD1PC69 with BILLS
2 

•HR 4911 IH

1 ‘‘(f) Growth hormone, recombinant human growth 

2 hormone, or human growth hormone.’’. 

3 (b) EFFECTIVE DATE.—The amendment made by 

4 this section shall take effect 60 days after the date of en5 actment of this Act. 

Æ 


bajohnson on PROD1PC69 with BILLS
Independent Auditors' Report


To the Shareholders and Board of Trustees of
Smith Barney Investment Series:

In planning and performing our audit of the financial statements of
the Smith Barney Large Cap Core Fund of Smith Barney Investment
Series. (the Fund) for the year ended October 31, 2001, we considered
its internal control, including control activities for safeguarding
securities, in order to determine our auditing procedures for the
purpose of expressing our opinion on the financial statements and to
comply with the requirements of Form N-SAR, not to provide assurance
on the internal control.

The management of the Fund is responsible for establishing and
maintaining internal control.  In fulfilling this responsibility,
estimates and judgments by management are required to assess the
expected benefits and related costs of controls.  Generally, controls
that are relevant to an audit pertain to the entity's objective of
preparing financial statements for external purposes that are fairly
presented in conformity with accounting principles generally accepted
in the United States of America. Those controls include the
safeguarding of assets against unauthorized acquisition, use, or
disposition.

Because of inherent limitations in internal control, errors or fraud
may occur and not be detected.  Also, projection of any evaluation of
internal control to future periods is subject to the risk that it may
become inadequate because of changes in conditions or that the
effectiveness of the design and operation may deteriorate.

Our consideration of the internal control would not necessarily
disclose all matters in the internal control that might be material
weaknesses under standards established by the American Institute of
Certified Public Accountants.  A material weakness is a condition in
which the design or operation of one or more of the internal control
components does not reduce to a relatively low level the risk that
misstatements caused by error or fraud in amounts that would be
material in relation to the financial statements being audited may
occur and not be detected within a timely period by employees in the
normal course of performing their assigned functions.  However, we
noted no matters involving the internal control and its operation,
including controls for safeguarding securities that we consider to be
material weaknesses as defined above as of October 31, 2001.

This report is intended solely for the information and use of
management, the Board of Trustees of the Fund, and the Securities and
Exchange Commission and is not intended to be and should not be used
by anyone other than these specified parties.


New York, New York
December 12, 2001
EXHIBIT 31

                      CERTIFICATION PURSUANT TO SECTION 302
                        OF THE SARBANES-OXLEY ACT OF 2002

                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
                           AND CHIEF FINANCIAL OFFICER

    I, John M. Sharpe, Jr., President, Chief Executive Officer and Chief
Financial Officer of Inner Systems, Inc., certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Inner Systems, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report.

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report.

4. I am responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the
registrant and I have:

    (a) designed such disclosure controls and procedures to ensure that material
        information relating to the registrant, including its consolidated
        subsidiaries, is made known to me by others within those entities,
        particularly during the period in which this report is being prepared;

    (b) evaluated the effectiveness of the registrant's disclosure controls and
        procedures and presented in this report my conclusions about the
        effectiveness of the disclosure controls and procedures based on such
        evaluation.

5. I have disclosed, based upon my most recent evaluation, to the registrant's
auditors and the audit committee of the registrant's board of directors (or
persons fulfilling the equivalent function):

    (a) all significant deficiencies in the design or operation of internal
        controls which could adversely affect the registrant's ability to
        record, process, summarize and report financial data and have identified
        for the registrant's auditors any material weaknesses in internal
        controls; and

    (b) any fraud, whether or not material, that involves management or other
        employees who have a significant role in the registrant's internal
        controls.

6. I have indicated in this annual report whether or not there were significant
changes in internal controls or in other factors that could significantly affect
internal controls subsequent to the date of our most recent evaluation,
including any corrective actions with regard to significant deficiencies and
material weaknesses.

Date:  May 20, 2005                     /s/ John M. Sharpe, Jr.
                                        -----------------------
                                        John M. Sharpe, Jr.
                                        President, Chief Executive Officer
                                        and Chief Financial Officer
```

[Congressional Bills 113th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1503 Introduced in House (IH)]

113th CONGRESS
  1st Session
                                H. R. 1503

    To repeal a certain rule relating to nutrition standards in the 
  national school lunch and school breakfast programs, and for other 
                               purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 11, 2013

    Mr. King of Iowa (for himself and Mr. Huelskamp) introduced the 
 following bill; which was referred to the Committee on Education and 
                             the Workforce

_______________________________________________________________________

                                 A BILL

 
    To repeal a certain rule relating to nutrition standards in the 
  national school lunch and school breakfast programs, and for other 
                               purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``No Hungry Kids Act''.

SEC. 2. REPEAL OF RULE.

    The rule prescribed by the Food and Nutrition Service of the 
Department of Agriculture relating to nutrition standards in the 
national school lunch and school breakfast programs published on 
January 26, 2012 (77 Fed. Reg. 4088 et seq.) and revising parts 210 and 
220 of title 7, Code of Federal Regulations, shall have no force or 
effect.

SEC. 3. LIMITS ON CERTAIN NUTRITIONAL REQUIREMENTS.

    Section 9(a)(1)(A)(i) of the Richard B. Russell National School 
Lunch Act (42 U.S.C. 1758(a)(1)(A)(i)) is amended by inserting before 
the semicolon the following: ``, to establish a calorie maximum for 
individual school lunches, or to prohibit a child from eating a lunch 
provided by the child's parent or legal guardian''.
                                 <all>
```
<TABLE> <S> <C>

<ARTICLE> 6
<CIK> 0000797480
<NAME> Smith Barney Natural Resources Fund
<SERIES>
   <NUMBER>001
   <NAME>Smith Barney Sector Series Inc.

<S>                         <C>
<PERIOD-TYPE>              Year
<FISCAL-YEAR-END>                 Oct-31-2001
<PERIOD-END>                      Oct-31-2000
<INVESTMENTS-AT-COST>              30,963,082
<INVESTMENTS-AT-VALUE>             35,234,998
<RECEIVABLES>                          13,928
<ASSETS-OTHER>                      1,867,783
<OTHER-ITEMS-ASSETS>                        0
<TOTAL-ASSETS>                     37,116,709
<PAYABLE-FOR-SECURITIES>                    0
<SENIOR-LONG-TERM-DEBT>                     0
<OTHER-ITEMS-LIABILITIES>           1,867,671
<TOTAL-LIABILITIES>                 1,867,671
<SENIOR-EQUITY>                             0
<PAID-IN-CAPITAL-COMMON>           49,189,850
<SHARES-COMMON-STOCK>                 136,642
<SHARES-COMMON-PRIOR>                 163,845
<ACCUMULATED-NII-CURRENT>               4,416
<OVERDISTRIBUTION-NII>                      0
<ACCUMULATED-NET-GAINS>           (18,217,144)
<OVERDISTRIBUTION-GAINS>                    0
<ACCUM-APPREC-OR-DEPREC>            4,271,916
<NET-ASSETS>                       35,249,038
<DIVIDEND-INCOME>                     727,281
<INTEREST-INCOME>                      37,079
<OTHER-INCOME>                              0
<EXPENSES-NET>                        898,014
<NET-INVESTMENT-INCOME>              (133,654)
<REALIZED-GAINS-CURRENT>           (4,223,990)
<APPREC-INCREASE-CURRENT>           5,553,665
<NET-CHANGE-FROM-OPS>               1,196,021
<EQUALIZATION>                              0
<DISTRIBUTIONS-OF-INCOME>                   0
<DISTRIBUTIONS-OF-GAINS>                    0
<DISTRIBUTIONS-OTHER>                       0
<NUMBER-OF-SHARES-SOLD>               127,383
<NUMBER-OF-SHARES-REDEEMED>           154,586
<SHARES-REINVESTED>                         0
<NET-CHANGE-IN-ASSETS>            (12,738,115)
<ACCUMULATED-NII-PRIOR>                 4,896
<ACCUMULATED-GAINS-PRIOR>         (15,316,808)
<OVERDISTRIB-NII-PRIOR>                     0
<OVERDIST-NET-GAINS-PRIOR>                  0
<GROSS-ADVISORY-FEES>                 326,909
<INTEREST-EXPENSE>                          0
<GROSS-EXPENSE>                       898,014
<AVERAGE-NET-ASSETS>                2,895,899
<PER-SHARE-NAV-BEGIN>                  18.200
<PER-SHARE-NII>                        (0.110)
<PER-SHARE-GAIN-APPREC>                 0.370
<PER-SHARE-DIVIDEND>                    0.000
<PER-SHARE-DISTRIBUTIONS>               0.000
<RETURNS-OF-CAPITAL>                    0.000
<PER-SHARE-NAV-END>                    19.230
<EXPENSE-RATIO>                          2.30



</TABLE>
(a)
    
    Designed such disclosure controls and procedures, or caused such disclosure controls and
procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiaries, was made known to us by others
within those entities, particularly during the period in which this report was being prepared;
 (b)
    
    Designed such internal control over financial reporting, or caused such internal control over
financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;
 (c)
    
    Evaluated the effectiveness of the registrants disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation;
and
 (d)
    
    Disclosed in this report any change in the registrants internal control over financial
reporting that occurred during the registrants most recent fiscal year that has materially
affected, or is reasonably likely to materially affect, the registrants internal control over
financial reporting; and
  (a)
    
    All significant deficiencies and material weaknesses in the design or operation of internal
control over financial reporting which are reasonably likely to adversely affect the
registrants ability to record, process, summarize and report financial information; and
 (b)
    
    Any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrants internal control over financial reporting.
  /s/ GRANT A. CHRISTIANSON

Grant A. ChristiansonChief Financial Officer and Chief Accounting Officer(Principal Financial and Accounting Officer)
I 

110TH CONGRESS 

1ST SESSION H. R. 4872 

To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene. 

IN THE HOUSE OF REPRESENTATIVES 

DECEMBER 19, 2007 

Mr. CLAY introduced the following bill; which was referred to the Committee 

on Ways and Means 

A BILL 

To suspend temporarily the duty on 1-Amino-2,6- 

dimethylbenzene. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. 1-AMINO-2,6-DIMETHYLBENZENE. 

4 (a) IN GENERAL.—Subchapter II of chapter 99 of 

5 the Harmonized Tariff Schedule of the United States is 

6 amended by inserting in numerical sequence the following 

7 new heading: 

‘‘ 9902.l.l 1-Amino-2,6- 

dimethylbenzene (CAS No. 

87–62–7) (provided for in 

subheading 2921.49.50) ...... Free No change No change On or before 

12/31/2011 ’’. 


bajohnson on PROD1PC69 with BILLS
2 

•HR 4872 IH

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies to articles entered, or withdrawn 

3 from warehouse for consumption, on or after the 15th day 

4 after the date of the enactment of this Act. 

Æ 


bajohnson on PROD1PC69 with BILLS
<PAGE>
                                                                    EXHIBIT 23.2

                       CONSENT OF INDEPENDENT ACCOUNTANTS

     We hereby consent to the incorporation by reference in the Registration
Statements of Millennium Chemicals Inc. on Form S-8 (No. 333-13143) pertaining
to the Quantum Chemical Retirement Savings & Investment Plan, (No. 333-13147)
pertaining to Quantum Chemical Retirement Savings & Investment Plan for Hourly
Represented Employees, and (No. 333-13717) pertaining to the Millennium
Chemicals Inc. Long Term Stock Incentive Plan of our reports dated (i) November
13, 1996 with respect to the consolidated financial statements of
Cornerstone-Spectrum, Inc. and (ii) November 7, 1995, except for Note 12, as to
which the date is July 2, 1996 with respect to the consolidated financial
statements of HMB Holdings, Inc. included in the Annual Report (Form 10-K) of
Millennium Chemicals Inc. for the year ended December 31, 1997.

                                          ERNST & YOUNG LLP

Hackensack, New Jersey
March 27, 1998
TRAVELERS SERIES FUND INC.
on behalf of the 
Putnam Diversified Income Portfolio
	Supplement dated June 3, 1997 to 
	Prospectus dated February 28, 1997


	Effective March 31, 1997, Gail S. Attridge and Kenneth J. Taub replaced 
Neil J. Powers and Mark J. Siegel and have joined D. William Kohli and Robert 
M. Paine in the day-to-day management of the Putnam Diversified Income 
Portfolio.  Ms. Attridge is Senior Vice President at Putnam Investment 
Management, Inc. (Putnam Management).  She is Head of the Emerging Markets 
Fixed Income Group.  Prior to 1993, Ms. Attridge was an International Fixed 
Income Analyst for Keystone Custodian Funds, Inc. Mr. Taubes is Senior Vice 
President at Putnam Management.  He is Senior Portfolio Manager for the 
Taxable Investment-Grade Group, responsible for the overall investment 
strategies of Putnams active institutional portfolios.  Prior to 1991, Mr. 
Taubes was Senior Vice President, Finance Division at United States Trust 
Company of Boston.






FD 01302